Viral Infections in HSCT: Detection, Monitoring, Clinical Management, and Immunologic Implications.
Viral Infections in HSCT: Detection, Monitoring, Clinical Management, and Immunologic Implications.
复制标题
DOI：
10.3389/fimmu.2020.569381
复制
发表时间：
2020
影响因子：
7.3
通讯作者：
Onida F
中科院分区：
文献类型：
--
作者：
Annaloro C;Serpenti F;Saporiti G;Galassi G;Cavallaro F;Grifoni F;Goldaniga M;Baldini L;Onida F
尽管越来越多的研究，病毒感染和异基因造血干细胞移植（HSCT）之间的关系仍然存在争议，几乎完全涉及DNA病毒。病毒感染本身是HSCT接受者发病和死亡的相当大的风险，并且可用的抗病毒药剂已被证明有效性有限。因此，病毒感染的最佳管理是HSCT策略的关键点。另一方面，病毒具有影响HSCT后免疫恢复的潜力，可能干扰基础疾病和移植物抗宿主病（GvHD）的控制，并最终影响HSCT结果。此外，关于一些病毒组成分作为HSCT后免疫恢复标志物的可能作用，已有初步数据。最后，HSCT可能对某些病毒感染（特别是HIV和HTLV-1）产生免疫抑制作用，并被认为是这些适应症的根除方法。
In spite of an increasing array of investigations, the relationships between viral infections and allogeneic hematopoietic stem cell transplantation (HSCT) are still controversial, and almost exclusively regard DNA viruses. Viral infections per se account for a considerable risk of morbidity and mortality among HSCT recipients, and available antiviral agents have proven to be of limited effectiveness. Therefore, an optimal management of viral infection represents a key point in HSCT strategies. On the other hand, viruses bear the potential of shaping immunologic recovery after HSCT, possibly interfering with control of the underlying disease and graft-versus-host disease (GvHD), and eventually with HSCT outcome. Moreover, preliminary data are available about the possible role of some virome components as markers of immunologic recovery after HSCT. Lastly, HSCT may exert an immunotherapeutic effect against some viral infections, notably HIV and HTLV-1, and has been considered as an eradicating approach in these indications.